An indisputable fact in any Alzheimer's reasearch area is the importance of an early detection.
One unique aspect of Eli Lilly and Company's TRAILBLAZER-ALZ 2 trial for anti-amyloid #donanemab is that patients stopped receiving the drug once PET scans showed that the drug had cleared #amyloid plaques in the brain. Considering that including stopping rules in a trial is innovative for #Alzheimers research, it's likely that the FDA would like to learn more about this practice in the forthcoming Advisory Committee. ADDF Co-Founder and Chief Science Officer, Howard Fillit, MD, discussed the trial and the economic and clinical benefits of ceasing drug administration once amyloid is cleared with Endpoints News: https://bit.ly/4a3Aqly Ryan Cross
